Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation
Copyright policy )Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation
Abstract Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable milestones in the treatment of B-cell malignancies. However, cancer cells frequently survive CAR T-cell killing in a large cohort of patients. Relapse oftentimes is associated with antigen loss. In this issue, Im and colleagues report a new mechanism of leukemic-cell resistance to anti-CD19 CAR T cells: Leukemic cells can enable a B-cell activation and germinal center reaction signature, which causes CD19 transcriptional downregulation and survival from CAR exposure. See related article by Im et al., p. 1055 (5).
- Cleveland Clinic United States
Lymphoma, B-Cell, T-Lymphocytes, Antigens, CD19, Receptors, Antigen, T-Cell, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Germinal Center, Immunotherapy, Adoptive
Lymphoma, B-Cell, T-Lymphocytes, Antigens, CD19, Receptors, Antigen, T-Cell, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Germinal Center, Immunotherapy, Adoptive
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).1 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!